Hematopoietic stem cell transplantation for primary cutaneous ?? T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma - 16/05/15
Abstract |
Background |
The panniculitic T-cell lymphomas (TCLs) comprise 2 distinct entities, αβ subcutaneous panniculitis-like TCL (SPTCL) and the γδ cutaneous TCLs with pannicular involvement primary cutaneous γδ (PCGD)-TCL. Although outcomes for most patients with SPTCL are favorable, those with PCGD-TCLs generally have an inferior outcome, and treatment strategies have not been well defined. Allogeneic hematopoietic stem cell transplantation (HSCT) has been shown to be a potentially curative strategy in aggressive TCLs and in refractory and advanced-stage mycosis fungoides.
Objective |
We sought to analyze the outcomes of HSCT for panniculitic cutaneous TCL.
Results |
Fourteen patients (4 SPTCL, 10 PCGD-TCL) presented with primarily pannicular T-cell infiltrates. Seven patients underwent allogeneic HSCT from matched-related donors and matched-unrelated donors of which 4 (57%) are alive (1 SPTCL, 3 PCGD-TCL) at 7.8, 6.9, 6.2, and 0.25 years. Two patients underwent autologous HSCT (1 SPTCL, 1 PCGD-TCL) and both are alive at a median follow-up of 1.91 years.
Limitations |
This study is limited by its retrospective nature and small sample size because of the rarity of SPTCL and PCGD-TCL.
Conclusion |
Aggressive therapy followed by allogeneic HSCT is a promising treatment modality for patients with PCGD-TCL.
Le texte complet de cet article est disponible en PDF.Key words : γ-δ, hematopoietic stem cell transplantation, primary cutaneous γδ T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, T-cell lymphoma
Abbreviations used : CHOP, CHOP-E, CR, EORTC, EPOCH, HSCT, PCGD, PD, PR, SCT, SD, SPTCL, TCL, WHO
Plan
Funding sources: None. |
|
Conflicts of interest: None declared. |
Vol 72 - N° 6
P. 1010 - juin 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?